Catastrophic Antiphospholipid Syndrome (CAPS / Asherson's Syndrome): Multi-Organ Microvascular Thrombosis Storm Within One Week and Triple Therapy with Plasmapheresis¶

Catastrophic Antiphospholipid Syndrome (CAPS, also eponymously known as Asherson's Syndrome after Dr. Ronald Asherson, who first described it in 1992) is the most fulminant, life-threatening variant of Antiphospholipid Syndrome (APS), striking less than 1 percent of APS patients (with nearly 50 percent of cases occurring as the very first clinical presentation in a patient who never knew they had APS). Whereas classic APS typically causes a single large-vessel venous or arterial clot (such as a single deep vein thrombosis, pulmonary embolism, or stroke) or recurrent pregnancy loss, CAPS is an explosive, complement-amplified "thrombotic storm" (Thrombotic Microangiopathy [TMA] + systemic inflammatory response syndrome [SIRS]) that simultaneously occludes the small microvessels of three or more organ systems within less than 7 days, most frequently the kidneys (73%: malignant hypertension, proteinuria, and acute renal failure), lungs (60%: ARDS, pulmonary embolism, and diffuse alveolar hemorrhage), brain (56%: stroke, seizures, cerebral venous thrombosis, and encephalopathy), heart (50%: myocardial micro-infarction and Libman-Sacks valve vegetations), skin (47%: livedo racemosa, painful digital ischemia, and cutaneous necrosis), and adrenal glands (bilateral adrenal hemorrhage/infarction causing refractory hypotensive shock). Because CAPS is driven by a "Two-Hit" mechanism, where preexisting high-titer antiphospholipid antibodies (Lupus Anticoagulant [LA], Anti-Cardiolipin [aCL] IgG/IgM, i Anti-Beta-2-Glycoprotein-I [aB2GPI] IgG/IgM) are ignited by an acute "Second Hit" trigger (bacterial or viral infection in 49%, surgical procedures or trauma in 17%, abrupt withdrawal or subtherapeutic INR of Warfarin, malignancy, pregnancy/puerperium, or oral contraceptive estrogen), delaying treatment carries an 80 to 90 percent stopa smrtnosti, dok trenutni početak CAPS "trostruke terapije" u intenzivnoj njezi smanjuje smrtnost na pola. Ako je pacijent s poznatim lupusom (SLE), Antiphospholipid Syndrome, or unexplained thrombocytopenia develops sudden multi-organ symptoms (shortness of breath, confusion, chest or flank pain, mottled purple skin, or dark/absent urine), call your local hitne brojeve immediately. Also review our companion guides on adrenal crisis and Addison's disease emergency injection, eclampsia seizures, HELLP syndrome, and postpartum preeclampsia, i sepsis and septic shock.

Your immediate emergency department and ICU priority is to launch full empiric "CAPS Triple Therapy" simultaneously at the very first clinical suspicion of multi-organ microvascular thrombosis (WITHOUT waiting days for confirmatory antiphospholipid antibody titers or tissue biopsy): (1) Therapeutic Intravenous Unfractionated Heparin (UFH) (not only to halt fibrin clot propagation, but because heparin directly inhibits complement activation [C3/C5 convertase]), (2) High-Dose Intravenous Corticosteroids (Methylprednisolone 500 to 1,000 mg/day IV for 3 days, followed by 1 to 2 mg/kg/day) (to extinguish the NF-kappa-B endothelial cytokine storm), and (3) Immediate Daily Therapeutic Plasma Exchange (Plasmapheresis / TPE exchanging 1.0 to 1.5 plasma volumes against Fresh Frozen Plasma/Albumin) AND/OR High-Dose Intravenous Immunoglobulin (IVIG, 0.4 g/kg/day IV for 5 days), while treating the underlying infectious trigger with broad-spectrum antibiotics and deploying the anti-C5 terminal complement inhibitor Eculizumab (Soliris) or anti-CD20 Rituximab for refractory cases.

Učinite to sada¶

1. Call your local emergency number or trigger an immediate ICU / Hematology / Rheumatology Rapid Response if a patient develops simultaneous thrombosis or acute organ dysfunction in >= 2 to 3 organs within a week. Dial 911 u Sjedinjenim Državama i Kanadi, 999 u Ujedinjenom Kraljevstvu, 112 diljem Europske unije, 000 in Australia, or consult our directory of hitne brojeve. Remember that 46 to 50 percent of CAPS patients have NO prior diagnosis of APS or Lupus (SLE) before walking into the emergency room.
2. Start Pillar 1 of CAPS Triple Therapy Immediately: Therapeutic Intravenous Unfractionated Heparin (UFH) (Even in the Presence of Moderate Thrombocytopenia or Diffuse Alveolar Hemorrhage).
3. Nefrakcionirani heparin obavezni je kamen temeljac preživljavanja CAPS-a (reducing mortality from > 75% to about 30% u Međunarodnom registru CAPS) i putem antikoagulacije posredovane antitrombinom i izravne inhibicije klasičnih i alternativnih putova komplementa.
4. Biser kritičnog laboratorijskog praćenja (The Lupus Anticoagulant aPTT Trap): Budući da pacijent cirkulira Lupus antikoagulant (LA) antitijela umjetno produljuju početnu vrijednost ovisnu o fosfolipidima aPTT (often to 60 to 100+ seconds prije nego što se počne s heparinom), praćenje IV nefrakcioniranog heparina standardom aPTT će vas prevariti u ozbiljno premalo doziranje heparina. Uvijek pratite IV nefrakcionirani heparin u CAPS-u pomoću kromogenika Anti-Factor Xa (Anti-Xa) analiza (target 0.3 to 0.7 IU/mL), NIKADA standard aPTT.
5. Odmah započnite s 2. stupom CAPS trostruke terapije: pulsni intravenski metilprednizolon (500 to 1,000 mg IV Once Daily for 3 Consecutive Days, Slijedi 1 to 2 mg/kg/day IV). Nikada nemojte davati kortikosteroide same bez antikoagulacije u CAPS-u, ali uz IV heparin i plazmaferezu, visoka doza IV metilprednizolona isključuje Anti-Beta-2-Glikoprotein-I (aB2GPI) aktivacija endotela NF-kappa-B i Tissue Factor izraz i istovremeno pokriva akutno bilateralno krvarenje/infarkt nadbubrežne žlijezde (which complicates 13% to 26% of CAPS cases).
6. Započnite 3. stup CAPS trostruke terapije unutar nekoliko sati: dnevna terapijska izmjena plazme (Plasmapheresis / TPE) I/ILI visoka doza intravenskog imunoglobulina (IVIG).
7. Terapeutska izmjena plazme (TPE, Prva linija, posebno kada su šistociti / mikroangiopatska hemolitička anemija [MAHA] ili zatajenje bubrega): Razmjena 1.0 to 1.5 plasma volumes dnevno tijekom najmanje 3 do 5 dana koristeći svježe smrznutu plazmu (FFP) (or 50:50 FFP + 5% Albumin) za mehaničko uklanjanje patogenih aB2GPI i aCL autoantitijela, citokini (IL-1, IL-6, TNF-alpha), and complement fragments while replenishing natural anticoagulants (Antithrombin, Protein C, Protein S, and ADAMTS13).
8. High-Dose IVIG (0.4 g/kg/day IV for 5 days ili 1.0 g/kg/day for 2 days): Administer either alone (if apheresis catheter placement or TPE is delayed) or immediately after each daily Plasma Exchange session (never infuse IVIG right *before* a TPE session, or the apheresis machine will wash your expensive IVIG straight into the waste bag).
9. Hunt Down and Aggressively Treat the "Second-Hit" Precipitating Trigger (Infection in 49% of Cases). Draw STAT peripheral and line blood cultures, urine cultures, and viral panels, and start empiric broad-spectrum intravenous antibiotics immediately if any fever or infectious source is suspected. Never abruptly stop anticoagulation before surgery in a known Triple-Positive APS patient (always bridge closely with IV UFH or therapeutic LMWH).
10. Postavite inhibiciju terminalnog komplementa (IV Eculizumab 900 mg Tjedno) ili Rituximab Early in Refractory CAPS or Prominent TMA (Schistocytes + Severe Thrombocytopenia + Renal Failure). Experimental and clinical evidence proves that severe CAPS is driven by runaway Terminal Complement Complex (C5b-9 membrane attack complex) deposition on endothelial cells (often with underlying complement regulatory gene mutations). Giving IV Eculizumab (Soliris) halts intravascular hemolysis, thrombocytopenia, and renal microvascular thrombosis within 48 to 72 hours when standard Triple Therapy is not enough.

Decision tree: suspected Catastrophic Antiphospholipid Syndrome (CAPS / Asherson's Syndrome) and ICU Triple Therapy¶

flowchart TD
    Patient["Patient Presents With Rapidly Progressive Multi-Organ Dysfunction (>= 3 Organs Within < 7 Days):<br/>- Renal: Acute Kidney Injury, Malignant HTN, Proteinuria<br/>- Pulmonary: ARDS / Diffuse Alveolar Hemorrhage / PE<br/>- CNS: Encephalopathy, Stroke, Seizures, CVST<br/>- Cardiac: Elevated Troponin, Myocardial Microthrombi<br/>- Skin: Livedo Racemosa, Digital Gangrene, Skin Necrosis<br/>- Adrenal: Flank/Abdominal Pain + Refractory Hypotension"] --> StatWorkup["STAT Bedside & Lab Triage (Do NOT Delay Treatment for Antibody Results):<br/>1. Peripheral Smear (Schistocytes), LDH, Haptoglobin, Platelets, Coags, Fibrinogen<br/>2. Draw Lupus Anticoagulant (dRVVT/aPTT), Anti-Cardiolipin IgG/IgM, & Anti-Beta-2-Glycoprotein-I IgG/IgM (BEFORE Plasma Exchange)<br/>3. Draw Random Cortisol & ACTH (Check for Bilateral Adrenal Hemorrhage) + ADAMTS13 Activity (Rule Out TTP)"]

    StatWorkup --> TripleTherapy["LAUNCH EMPIRIC 'CAPS TRIPLE THERAPY' IMMEDIATELY IN THE ICU"]

    TripleTherapy --> Pillar1["PILLAR 1: Therapeutic IV Unfractionated Heparin (UFH)<br/>- Monitor Strictly With Chromogenic ANTI-FACTOR Xa Level (Target 0.3 to 0.7 IU/mL)<br/>- NEVER Monitor With Standard aPTT (Falsely Prolonged by Lupus Anticoagulant)"]

    TripleTherapy --> Pillar2["PILLAR 2: High-Dose IV Corticosteroids<br/>- IV Methylprednisolone 500 to 1,000 mg Daily for 3 Days, Then 1 to 2 mg/kg/day<br/>- Blocks NF-kappa-B Endothelial Storm & Treats Adrenal Crisis"]

    TripleTherapy --> Pillar3["PILLAR 3: Daily Therapeutic Plasma Exchange (TPE) +/- High-Dose IVIG<br/>- Exchange 1.0 to 1.5 Plasma Volumes Daily x 5+ Days Using Fresh Frozen Plasma (FFP)<br/>- Infuse IVIG (0.4 g/kg/day x 5 Days) AFTER Each TPE Session (Never Right Before TPE)"]

    Pillar1 --> TriggerAndRefractory{"Treat 'Second-Hit' Trigger (Empiric Broad-Spectrum Antibiotics if Any Infection) & Assess 24-to-48-Hour Response"}
    Pillar2 --> TriggerAndRefractory
    Pillar3 --> TriggerAndRefractory

    TriggerAndRefractory -->|"Refractory Thrombocytopenia, Ongoing MAHA Schistocytes, or Worsening Organ Failure"| AddEculizumab["ESCALATE IMMEDIATELY:<br/>1. IV Eculizumab (Anti-C5 Complement Inhibitor: 900 mg IV Weekly x 4, Then 1,200 mg) [Give Meningococcal Vaccine + Ciprofloxacin/Penicillin Prophylaxis]<br/>2. IV Rituximab (375 mg/m2 Weekly x 4) to Deplete B-Cell Autoantibody Production"]

Part 1: The "Two-Hit" Pathophysiology of Asherson's Syndrome and International Diagnostic Criteria¶

1. Why Quiet Antiphospholipid Antibodies Suddenly Explode Into a 7-Day Multi-Organ Storm¶

Many individuals walk around for years with circulating "Triple-Positive" antiphospholipid antibodies (Lupus Anticoagulant + Anti-Cardiolipin + Anti-Beta-2-Glycoprotein-I) without developing a blood clot ("The First Hit"). Why? Because under normal resting conditions, vascular endothelial cells hide negatively charged membrane phospholipids on their inner leaflet, and circulating Beta-2-Glycoprotein-I (B2GPI) floats in a closed circular conformation that conceals its antigenic binding domain (Domain I).

• The "Second Hit" Trigger (Infection, Surgery, Trauma, Pregnancy, or Warfarin Withdrawal):
• When an infection (Gram-negative sepsis, respiratory virus, urinary tract infection), surgical tissue trauma, or obstetrical complication damages or activates vascular endothelial cells, negatively charged phosphatidylserine flips to the outer cell surface.
• Circulating B2GPI binds to the damaged endothelium and uncoils into an open "J-shaped fishhook" conformation, exposing Domain I.
• Pathogenic Anti-Beta-2-Glycoprotein-I (aB2GPI) IgG dimers cross-link the open B2GPI molecules on endothelial cells, platelets, and monocytes via Toll-Like Receptor 4 (TLR4) and Annexin A2, activating NF-kappa-B i p38 MAPK.
• The Complement Amplification Loop (C3a / C5a / C5b-9): The bound aB2GPI immune complexes trigger massive activation of the Classical and Alternative Complement Pathways, generating anaphylatoxins C3a i C5a (which recruit neutrophils to extrude prothrombotic NETs) and punching C5b-9 Membrane Attack Complex pores into microvascular endothelial cells throughout the kidneys, lungs, brain, heart, and adrenal glands.

2. Official Preliminary Classification Criteria for Catastrophic APS (Asherson et al. International Consensus)¶

Clinicians classify a patient as having Definite CAPS (all 4 criteria) or Probable CAPS (3 of 4 criteria) based on: 1. Criterion 1 (>= 3 Organs, Systems, or Tissues): Clinical evidence of involvement of three or more organs, systems, and/or tissues (renal, pulmonary, cerebral, cardiac, cutaneous, hepatic, gastrointestinal/mesenteric, splenic, or adrenal). 2. Criterion 2 (<= 7 Days): Development of clinical manifestations simultaneously or in less than one week. 3. Criterion 3 (Histopathologic Microthrombosis): Confirmation by histopathology of small-vessel occlusion (thrombotic microangiopathy) in at least one organ or tissue (typically via skin punch biopsy of livedo/necrotic lesions or renal biopsy once stabilized). 4. Criterion 4 (Laboratory Antiphospholipid Antibodies): Presence of Lupus Anticoagulant (LA), Anti-Cardiolipin (aCL IgG/IgM at medium-to-high titer > 40 GPL/MPL ili > 99th percentile), and/or Anti-Beta-2-Glycoprotein-I (aB2GPI IgG/IgM).

• When to Diagnose "Probable CAPS" and Treat Immediately at the Bedside: Because performing a kidney biopsy in a critically ill, anticoagulated, thrombocytopenic ICU patient is dangerous and waiting 12 weeks for repeat antibody confirmation is impossible during an acute crisis, the International Consensus defines Probable CAPS whenever:
• Only 2 organs are involved (with Criteria 2, 3, and 4 met), OR
• All 4 criteria are met except histopathologic biopsy confirmation is missing (because the patient is too unstable/anticoagulated to biopsy), OR
• 3 organs develop thrombosis over 1 to 4 weeks despite anticoagulation.
• Clinical Rule: Treat Probable CAPS identically to Definite CAPS with immediate full Triple Therapy.

Part 2: Side-by-Side Differential Diagnosis of ICU Thrombotic Microangiopathies (CAPS vs. TTP vs. HUS/aHUS vs. HIT vs. Sepsis DIC)¶

When an ICU patient develops rapidly falling platelets, rising creatinine, neurological confusion, and hemolytic anemia with schistocytes (helmet cells) on the blood smear, distinguishing CAPS from Thrombotic Thrombocytopenic Purpura (TTP), Complement-Mediated Hemolytic Uremic Syndrome (aHUS), HIT, and Septic DIC is critical:

Part 3: Deep-Dive Into the 6 Organ Emergencies of CAPS (Including Bilateral Adrenal Hemorrhage & Diffuse Alveolar Hemorrhage)¶

When managing a CAPS patient in the ICU, clinicians must actively screen for and manage six signature organ crises that determine survival:

========================================================================
   THE 6 SIGNATURE MULTI-ORGAN THROMBOTIC CRISES OF CAPS (ASHERSON'S)
========================================================================

  1. RENAL TMA (73%):               2. PULMONARY CRISIS (60%):
     Renal interlobular/glomerular     ARDS, Pulmonary Embolism, AND
     capillary microthrombi ->         Capillaritis DIFFUSE ALVEOLAR
     Malignant HTN + Oliguric AKI.     HEMORRHAGE (DAH: Hemoptysis +
                                       Falling Hb + Ground-Glass CT).
  3. CEREBRAL / CNS (56%):             * CRITICAL PEARL: Even with DAH,
     Microvascular Encephalopathy,       continue carefully titrated IV
     Seizures, Ischemic Stroke, &        Heparin + Pulse Steroids + TPE.
     Cerebral Venous Sinus Clots.
                                    4. CARDIAC MICRO-INFARCTION (50%):
  5. CUTANEOUS ISCHEMIA (47%):         Intramyocardial microthrombi
     Branching Livedo Racemosa,        (cardiogenic shock with clean
     Splinter Hemorrhages, Digital     epicardial coronaries) + Sterile
     Cyanosis/Gangrene, Skin Ulcers.   Libman-Sacks Mitral/Aortic Valves.

  6. BILATERAL ADRENAL HEMORRHAGE / INFARCTION (13% to 26% - OFTEN MISSED.):
     * Why the Adrenal Glands? Each adrenal gland is fed by 3 arteries
       (50-60 arterioles) but drained by ONLY A SINGLE CENTRAL ADRENAL VEIN.
     * Thrombosis of that single central adrenal vein causes hemorrhagic
       venous infarction of both adrenal cortices -> Sudden Flank/Abdominal
       Pain, Hyponatremia, Hyperkalemia, & Catecholamine-Resistant Shock.
     * Lifesaving Fix: Immediate Stress-Dose IV Hydrocortisone (100 mg IV
       bolus, then 50 mg IV q6h) or Pulse IV Methylprednisolone.
========================================================================

1. The Adrenal Vein Anatomical Bottleneck (Why CAPS Causes Acute Addisonian Adrenal Crisis)¶

Why is bilateral adrenal hemorrhage/infarction a classic complication of both CAPS and HIT? - Every human adrenal gland has a rich arterial supply (superior, middle, and inferior suprarenal arteries branching into 50+ capillary plexus vessels), but all venous blood must exit through a single, solitary Central Adrenal Vein (creating a vascular "water-hammer" bottleneck rich in platelet-activating catecholamines). - When CAPS microthrombi occlude that single central adrenal vein bilaterally, venous pressure inside the adrenal cortex skyrockets until the glands rupture and hemorrhage internally (Waterhouse-Friderichsen-like hemorrhagic infarction). - Clinical Red Flags: If a patient with APS/CAPS develops new bilateral flank, back, or epigastric pain, unexplained fever, falling serum sodium (hyponatremia), rising potassium (hyperkalemia), and hypotension refractory to norepinephrine, order an immediate Abdominal CT (which shows enlarged, hyperdense edematous adrenal glands), draw a STAT random serum Cortisol and ACTH, and immediately administer 100 mg IV Hydrocortisone bolus followed by 50 mg IV every 6 hours (or make sure the patient is already receiving Pulse IV Methylprednisolone).

2. The Pulmonary Paradox: Managing Diffuse Alveolar Hemorrhage (DAH) Inside a Prothrombotic Storm¶

Up to 60 percent of CAPS patients develop acute respiratory failure from ARDS, pulmonary thromboembolism, or non-thrombotic pulmonary capillaritis causing Diffuse Alveolar Hemorrhage (DAH: hemoptysis, diffuse bilateral alveolar infiltrates on chest CT, and a 1.5 to 3.0 g/dL overnight drop in hemoglobin). - How Can a Clotting Disease Cause Lung Bleeding? In CAPS, aB2GPI antibodies and C5a trigger immune-complex pulmonary capillaritis (neutrophilic inflammation that necroses the alveolar capillary wall) combined with pulmonary venular microthrombosis that raises hydrostatic capillary back-pressure until red blood cells pour into the air sacs. - How to Manage DAH in CAPS: 1. Immediately escalate immunosuppression with Pulse IV Methylprednisolone (1,000 mg/day IV x 3 days) + Daily Therapeutic Plasma Exchange (TPE) + IV Cyclophosphamide or Rituximab. 2. Carefully Balance Anticoagulation: If alveolar bleeding is life-threatening and platelets/fibrinogen are critically low, hold IV unfractionated heparin briefly for a few hours while administering Pulse Steroids and Plasma Exchange, but resume low-dose/titrated IV Unfractionated Heparin as soon as active hemoptysis stabilizes, because withholding heparin for days in CAPS allows microvascular thrombosis to destroy the brain, heart, and kidneys.

Part 4: Step-by-Step ICU Triple Therapy Execution & Refractory Rescue (Eculizumab & Rituximab)¶

1. The Exact CAPS Triple Therapy Checklist (McMaster / EULAR / International CAPS Registry Guidelines)¶

2. Second-Line Biologic Rescue for Refractory CAPS (Eculizumab i Rituximab)¶

If a CAPS patient continues to experience falling platelets, rising creatinine, new neurological deficits, or refractory microangiopathic hemolysis after 24 to 48 hours of Triple Therapy: 1. Terminal Complement Blockade (IV Eculizumab [Soliris] ili Ravulizumab [Ultomiris]): - Why It Works: Over 60 percent of patients with refractory CAPS harbor severe complement activation (and many carry heterozygous mutations in complement regulatory genes like CFH, CFI, or CD46 identical to atypical HUS). Eculizumab (a humanized monoclonal antibody against complement protein C5) blocks cleavage of C5 into C5a i C5b-9, arresting endothelial TMA destruction within 24 to 72 hours. - Dosing: 900 mg IV once weekly for 4 weeks, followed by 1,200 mg IV on Week 5 and every 2 weeks thereafter. - Mandatory Meningococcal Prophylaxis: Because blocking C5b-9 creates susceptibility to encapsulated Neisseria meningitidis, administer quadrivalent (MenACWY) and Serogroup B (MenB) meningococcal vaccines immediately AND start daily oral antibiotic prophylaxis (Ciprofloxacin 500 mg daily ili Penicillin V 500 mg twice daily) from Day 1 of Eculizumab (do not delay Eculizumab for 2 weeks waiting for vaccine immunity). 2. B-Cell Depletion (IV Rituximab): - Administer Rituximab (375 mg/m2 IV once weekly for 4 weeks, or 1,000 mg IV on Days 1 and 15) (infused after daily TPE) to eliminate CD20+ B-lymphocytes producing pathogenic antiphospholipid autoantibodies, particularly in CAPS patients with severe thrombocytopenia, diffuse alveolar hemorrhage, or cardiac/CNS involvement.

Regional emergency numbers and international CAPS registries¶

• United States and Canada: Dial 911 for any suspected multi-organ thrombosis or stroke/PE emergency. Follow the McMaster University Clinical Practice Guideline for the Diagnosis and Management of Catastrophic Antiphospholipid Syndrome (Blood Advances) and American College of Rheumatology (ACR) / ASH guidance.
• European Union and United Kingdom: Dial 112 across the EU or 999 in the UK. Follow the European Alliance of Associations for Rheumatology (EULAR) Recommendations for the Management of Antiphospholipid Syndrome in Adults (Tektonidou et al., Annals of the Rheumatic Diseases) and the British Society for Haematology (BSH) Guidelines. Clinicians worldwide can consult and log cases with the International CAPS Registry (ontocrf.costaisa.com/en/web/caps, hosted by the European Forum on Antiphospholipid Antibodies at Hospital Clínic in Barcelona, Spain, directed by Dr. Ricard Cervera).
• Australia and New Zealand: Dial 000 in Australia or 111 in New Zealand. Follow THANZ and Australian Rheumatology Association (ARA) ICU protocols for Triple Therapy and emergency Eculizumab access.

Često postavljana pitanja¶

How is Catastrophic Antiphospholipid Syndrome (CAPS) different from regular Antiphospholipid Syndrome (APS)?¶

In classic Antiphospholipid Syndrome (APS), patients typically experience a single isolated blood clot in a large vein or artery (such as a deep vein thrombosis in one leg, a pulmonary embolism, or a stroke) or recurrent pregnancy complications, with normal function in the rest of their organs. Catastrophic Antiphospholipid Syndrome (CAPS, or Asherson's Syndrome) affects less than 1 percent of APS patients and acts like a sudden, body-wide microvascular "thrombotic storm": instead of one large clot, tiny blood clots simultaneously plug the microscopic capillaries of three or more critical organs (usually the kidneys, lungs, brain, heart, skin, and adrenal glands) within less than 7 days, accompanied by severe systemic inflammation and a falling platelet count.

Why do doctors have to give three treatments at the exact same time ("Triple Therapy") to save a patient with CAPS?¶

Historical data from the International CAPS Registry (covering over 500 patients worldwide) proved that treating CAPS with blood thinners alone or steroids alone failed in the majority of cases, because CAPS has three self-reinforcing engines: (1) Runaway fibrin and complement clotting in small vessels, (2) A fierce inflammatory cytokine storm on the blood vessel walls, and (3) High concentrations of circulating antiphospholipid autoantibodies. "Triple Therapy" attacks all three engines simultaneously: Intravenous Unfractionated Heparin stops clot propagation and inhibits complement, High-Dose IV Methylprednisolone shuts down the endothelial cytokine storm, and Daily Therapeutic Plasma Exchange (Plasmapheresis) and/or IVIG physically removes and neutralizes the autoantibodies, cutting mortality from over 75 percent down to roughly 30 percent.

Why can't nurses and doctors use the standard aPTT blood test to monitor intravenous Heparin in a patient with CAPS?¶

Patients with CAPS almost always have a circulating antiphospholipid antibody called a "Lupus Anticoagulant" (LA). Paradoxically, although a Lupus Anticoagulant causes severe blood clotting inside the human body, inside a glass laboratory test tube it binds to the phospholipid reagents used to run the standard activated Partial Thromboplastin Time (aPTT) test, artificially making the patient's baseline aPTT look prolonged (for example, 85 seconds) before a single drop of heparin is even given. If a clinician uses the aPTT to titrate the heparin drip, they will mistakenly think the patient's blood is "already too thin" and turn the heparin drip down to sub-therapeutic levels while the patient clots to death. Instead, IV Heparin in CAPS must always be monitored with a chromogenic Anti-Factor Xa (Anti-Xa) blood level (targeting 0.3 to 0.7 IU/mL), which is unaffected by the Lupus Anticoagulant.

Why does CAPS frequently cause sudden, life-threatening Adrenal Crisis (Addisonian shock)?¶

Each of your two adrenal glands (which sit on top of the kidneys and produce life-sustaining cortisol and aldosterone) receives blood through dozens of small arteries, but drains all of its blood out through one single Central Adrenal Vein. During a CAPS thrombotic storm, micro-clots easily plug that single draining adrenal vein on both sides. With the exit vein blocked, arterial blood backs up inside both adrenal glands until they swell and rupture internally (bilateral adrenal hemorrhage and infarction). This wipes out the body's cortisol production overnight, causing severe flank or stomach pain, low sodium, high potassium, and fatal low blood pressure unless treated immediately with high-dose intravenous corticosteroids (Methylprednisolone or Hydrocortisone).

Why should patients with Triple-Positive APS or prior CAPS never be switched from Warfarin to a modern Direct Oral Anticoagulant (DOAC) pill like Rivaroxaban or Apixaban?¶

Multiple randomized clinical trials (including the TRAPS and ASTRO-APS trials) were halted early after discovering that patients with "Triple-Positive" Antiphospholipid Syndrome (positive for Lupus Anticoagulant, Anti-Cardiolipin, and Anti-Beta-2-Glycoprotein-I) who took Direct Oral Anticoagulants (DOACs such as rivaroxaban or apixaban) suffered a 4-fold to 7-fold higher rate of arterial strokes and heart attacks than patients taking Warfarin. Blocking only a single clotting factor (Factor Xa or Factor IIa) with a DOAC is often insufficient to stop the massive thrombin and complement surge driven by triple-positive antiphospholipid antibodies, and switching from Warfarin to a DOAC is a documented trigger for acute Catastrophic APS.

Izvori i službene upute¶

• McMaster University / ASH Clinical Practice Guideline (Legault K et al., Blood Advances): McMaster RARE-Bestpractices Clinical Practice Guideline for the Diagnosis and Management of the Catastrophic Antiphospholipid Syndrome (Triple Therapy: Anticoagulation, Glucocorticoids, and Plasma Exchange/IVIG).
• European Alliance of Associations for Rheumatology (EULAR, Tektonidou MG et al., Annals of the Rheumatic Diseases): EULAR Recommendations for the Management of Antiphospholipid Syndrome in Adults (Contraindication of DOACs in Triple-Positive APS and CAPS Management).
• International Consensus Statement on Classification Criteria and Treatment Guidelines for Catastrophic Antiphospholipid Syndrome (Asherson RA, Cervera R, et al., Lupus / Journal of Rheumatology): Preliminary Classification Criteria for Definite and Probable CAPS and Analysis of 500+ Patients from the International CAPS Registry.
• British Society for Haematology (BSH, Arachchillage DRJ et al.): Guidelines on the Investigation and Management of Antiphospholipid Syndrome and Catastrophic APS.
• New England Journal of Medicine (NEJM) Review (Garcia D, Erkan D): Diagnosis and Management of the Antiphospholipid Syndrome and Complement Inhibition in CAPS.

Povezani vodiči¶

• Adrenal crisis and Addison's disease emergency injection
• Heparin-induced thrombocytopenia (HIT) and VITT: 50 percent platelet drop on Day 5 to 10 and Argatroban
• Napadaji eklampsije, HELLP sindrom, postporođajna preeklampsija i trijaža magnezija
• Sepsa i septički šok
• Brojevi hitnih službi po državama